{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:49:52Z","timestamp":1761518992149,"version":"3.37.3"},"reference-count":113,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":1516,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although tamoxifen appears to markedly reduce breast cancer risk in women with a prior diagnosis of atypical hyperplasia or<jats:italic>in situ<\/jats:italic>carcinoma, it is not clear what other groups of women receive substantial benefit. Major breast chemoprevention priorities are to (1) develop new agents that (a) have fewer side effects, (b) are effective in ER\u2212 as well as tamoxifen\u2010resistant precancerous tissue, and (c) are compatible with hormone therapy; and (2) develop efficient clinical strategies including prognostic and predictive morphologic and molecular biomarkers. Breast tissue may be repeatedly sampled for evidence of intraepithelial neoplasia by fine needle aspiration, ductal lavage, or needle biopsy to select candidates at highest short\u2010term risk as well as to monitor response in small proof of principle studies prior to a large cancer incidence trial. Molecular marker expression may also be used to select a cohort most likely to respond to a particular agent. A large number of new agents are attractive as potential prevention agents and some are already in clinical prevention testing. Compounds which should be effective in ER+ precancerous tissue but may have a better side\u2010effect profile include new selective estrogen receptor modulators which lack uterine estrogen agonist activity, isoflavones, aromatase inactivators\/inhibitors for postmenopausal women, and gonadotropin\u2010releasing hormone regimens for premenopausal women. Retinoids, rexinoids, and deltanoids may be efficacious in ER+ tissue resistant to tamoxifen. Agents which should theoretically have activity in ER\u2212 or ER+ precancerous tissue include polyamine synthesis inhibitors, tyrosine kinase inhibitors, combined demethylating agents and histone deacetylase inhibitors, as well as metalloprotease and angiogenesis inhibitors. Sample Phase I and Phase II clinical trial designs are reviewed using modulation of molecular markers and breast intraepithelial neoplasia as the major endpoints.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2001.tb02727.x","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T19:52:58Z","timestamp":1279655578000},"page":"44-59","source":"Crossref","is-referenced-by-count":26,"title":["Beyond Tamoxifen"],"prefix":"10.1111","volume":"952","author":[{"given":"CAROL J.","family":"FABIAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BRUCE F.","family":"KIMLER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2659"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.24.1879"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4741.1998.460447.x"},{"key":"e_1_2_5_6_2","first-page":"867","article-title":"The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol","volume":"25","author":"Khan S.A.","year":"1999","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240501130"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.1997.tb00139.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.1995.tb00233.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240450208"},{"key":"e_1_2_5_11_2","first-page":"439","article-title":"Interaction with endothelial cells is a prerequisite for branching ductal\u2010alveolar morphogenesis and hyperplasia of preneoplastic human breast epithelial cells: regulation of estrogen","volume":"60","author":"Shekhar M.P.V.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90028-4"},{"key":"e_1_2_5_13_2","first-page":"787","article-title":"Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast","volume":"139","author":"Koukoulis G.K.","year":"1991","journal-title":"Correlations with their functions as receptors and cell adhesion molecules. Am. J. Pathol."},{"key":"e_1_2_5_14_2","first-page":"993","article-title":"Estrogen receptor expression of benign breast epithelium and its association with breast cancer","volume":"54","author":"Khan S.A.","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006029612990"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr65"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.45.6.513"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.10.1623"},{"key":"e_1_2_5_19_2","first-page":"285","article-title":"Altered expression of a structural protein (fodrin) within epithelial proliferation disease of the breast","volume":"141","author":"Simpson J.F.","year":"1992","journal-title":"Am. J. Pathol."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.9.697"},{"key":"e_1_2_5_21_2","first-page":"4158","article-title":"Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer","volume":"57","author":"Widschwendter M.","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.10.826"},{"key":"e_1_2_5_23_2","first-page":"3508","article-title":"Loss of p16INK4 expression of methylation is associated with lifespan extension of human mammary epithelial cells","volume":"58","author":"Huschtscha L.I.","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2096"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4741.1998.440252.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.1998.5549"},{"key":"e_1_2_5_27_2","first-page":"733","article-title":"Molecular analysis of premalignant and carcinoma in situ lesions of the human breast","volume":"149","author":"Steeg P.S.","year":"1996","journal-title":"Am. J. Pathol."},{"key":"e_1_2_5_28_2","first-page":"2562","article-title":"Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis","volume":"60","author":"Moinfar F.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_29_2","first-page":"4026","article-title":"A hypersensitive estrogen receptor\u2010\u03b1 mutation in premalignant breast lesions","volume":"60","author":"Fuqua S.A.W.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006026732129"},{"key":"e_1_2_5_31_2","first-page":"927","article-title":"In situ aromatization enhances breast tumor estradiol levels and cellular proliferation","volume":"58","author":"Yue W.","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970317)70:6<639::AID-IJC2>3.0.CO;2-W"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006081729828"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.4.1460"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006194700667"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5241.1491"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1650371"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.6.455"},{"key":"e_1_2_5_40_2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/90.20.1529","article-title":"Cyclooxygenase\u20102 inhibitors in tumorogenesis Part I","volume":"90","author":"Taketo M.M.","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.133.2.8344219"},{"key":"e_1_2_5_42_2","first-page":"3183","article-title":"Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor","volume":"60","author":"Hyder S.M.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_43_2","first-page":"585","article-title":"Immunohistochemical distribution and type IV collagenase in normal, benign, and malignant breast tissue","volume":"136","author":"Monteagudo C.","year":"1990","journal-title":"Am. J. Pathol."},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.437"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6687"},{"key":"e_1_2_5_46_2","first-page":"1999","article-title":"Microvessel quantification as a measure of angiogenic activity in benign breast tissue lesions: a marker for precancerous disease? Int","volume":"4","author":"Fregene T.A.","year":"1994","journal-title":"J. Oncol."},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01611175"},{"key":"e_1_2_5_48_2","first-page":"3736","article-title":"Insulin\u2010like growth factor\u20101 receptors are overexpressed and predict a low risk in human breast cancer","volume":"53","author":"Papa V.","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_5_49_2","first-page":"2463","article-title":"The insulin\u2010like growth factor I receptor protects tumor cells from apoptosis in vivo","volume":"55","author":"Resnicoff M.","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.17.1247"},{"key":"e_1_2_5_51_2","first-page":"2552","article-title":"Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells","volume":"54","author":"Ottaviano Y.L.","year":"1994","journal-title":"Cancer Res."},{"key":"e_1_2_5_52_2","first-page":"2279","article-title":"Demethylation of the estrogen receptor gene in estrogen receptor\u2010negative breast cancer cells can reactivate estrogen receptor gene expression","volume":"55","author":"Ferguson A.T.","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_5_53_2","first-page":"4346","article-title":"Aberrant methylation of the estrogen receptor and E\u2010cadherin 5\u2032 CpG islands increases with malignant progression in human breast cancer","volume":"60","author":"Nass S.J.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006186719322"},{"key":"e_1_2_5_55_2","first-page":"2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial","volume":"281","author":"Cummings S.R.","year":"1999","journal-title":"Multiple Outcomes of Raloxifene Evaluation. JAMA"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3172"},{"key":"e_1_2_5_57_2","unstructured":"Llombart\u2010Cussac A. M. Bellet V. Guillem\u2010Porta et al.2000. Efficacy and safety of two doses of the selective estrogen receptor modulator (SERM) Ly353381 in locally advanced or metastatic breast cancer (LAMBC)\u2014a randomized double blind phase 2 study. Proc. Am. Soc. Clin. Oncol.19:157a (abstract)."},{"key":"e_1_2_5_58_2","first-page":"1101","article-title":"Effects of soy isoflavones on estrogen and photoestrogen metabolism in premenopausal women","volume":"7","author":"Xu X.","year":"1998","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"e_1_2_5_59_2","first-page":"781","article-title":"Soy consumption alters endogenous estrogen metabolism in postmenopausal women","volume":"9","author":"Xu X.","year":"2000","journal-title":"Cancer Epidemiol. Biomakers Prev."},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(93)90022-O"},{"key":"e_1_2_5_61_2","first-page":"4112","article-title":"Decreased ovarian hormones during a soya diet: implications for breast cancer prevention","volume":"60","author":"Lu L.J.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0060227"},{"key":"e_1_2_5_63_2","unstructured":"Harper\u2010Wynne C.L. G.M. Ross N.P. Sacks et al.2000. Study of the biological effects of the aromatase inhibitor letrazole in healthy postmenopausal women: rationale for prevention. Breast Cancer Res. Treat.64:47 (Abst.)."},{"key":"e_1_2_5_64_2","doi-asserted-by":"crossref","unstructured":"Nabholtz J.M. J. Bonneterre A.U. Buzdar et al.1999. Preliminary results of two multi\u2010center trials comparing the efficacy and tolerability of Arimidex\u2122 (anastrozole) and tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res. Treat.57:31 (abstract).","DOI":"10.1016\/S0959-8049(99)81673-6"},{"key":"e_1_2_5_65_2","unstructured":"Weitzel J.N. M.C. Pike A.M. Daniels et al.2000. Safety of a gonadotrophin\u2010releasing hormone agonist (GnRHA)\u2010based hormonal chemoprevention for young women at high genetic risk for breast cancer. Breast Cancer Res. Treat.64:48 (Abst.)."},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.21.1847"},{"key":"e_1_2_5_67_2","first-page":"4992","article-title":"Progressive decrease in nuclear retinoic acid receptor \u03b2 messenger RNA level during breast carcinogenesis","volume":"57","author":"Xu X.C.","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_5_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.6.475"},{"key":"e_1_2_5_69_2","first-page":"479","article-title":"Beyond tamoxifen: the retinoid X receptor\u2010selective ligand LGD1069 (TARGRETIN) cause complete regression of mammary carcinoma","volume":"58","author":"Bischoff E.D.","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_5_70_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.5.418"},{"key":"e_1_2_5_71_2","first-page":"3371","article-title":"1\u03b1, 25\u2010dihydroxy\u2010vitamin D3 down regulates estrogen receptor abundance and suppresses estrogen actions in MCF\u20107 human breast cancer cells","volume":"6","author":"Swami S.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_5_72_2","unstructured":"Bonanni B F. Ramazzoto Frachid et al.2000. A randomized trial of fenretinide in HRT users using IGF\u20101 as a surrogate biomarker. San Antonio Breast Cancer Symposium Abstract 15 Reference available 12\/00."},{"key":"e_1_2_5_73_2","first-page":"97","article-title":"Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF\u20107 human breast adenocarcinoma in vivo","volume":"20","author":"Leveque J.","year":"2000","journal-title":"Anticancer Res."},{"key":"e_1_2_5_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199711000-00012"},{"key":"e_1_2_5_75_2","first-page":"2101","article-title":"Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor","volume":"60","author":"Harris R.E.","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_5_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1210"},{"key":"e_1_2_5_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.1135"},{"key":"e_1_2_5_78_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2000.s.015"},{"key":"e_1_2_5_79_2","unstructured":"Parker V.P. J.A. Sandberg J. Smith et al.2000. Phase I and pharmacokinetic studies of angiozyme a synthetic ribozyme targeting the VEGF receptor Flt\u20101. Proc. Am. Soc. Clin. Oncol.19:181a (abstract)."},{"key":"e_1_2_5_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240590818"},{"key":"e_1_2_5_81_2","first-page":"1159","article-title":"Phase I clinical trial of perillyl alcohol administered daily","volume":"4","author":"Ripple G.H.","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_5_82_2","first-page":"1917","article-title":"Activation of the transforming growth factor \u03b2 signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol","volume":"59","author":"Aziazi E.A.","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_5_83_2","first-page":"1464","article-title":"Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti\u2010inflammatory agent","volume":"55","author":"Rao C.V.","year":"1995","journal-title":"Cancer Res."},{"key":"e_1_2_5_84_2","first-page":"267","article-title":"Sulfone metabolite of sulindac inhibits mammary carcinogenesis","volume":"57","author":"Thompson H.J.","year":"1997","journal-title":"Cancer Res."},{"key":"e_1_2_5_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.240531007"},{"key":"e_1_2_5_86_2","first-page":"1133","article-title":"Mammographic densities and breast cancer risk","volume":"7","author":"Boyd N.F.","year":"1998","journal-title":"Cancer Epidemiol. Biomarkers Prevent."},{"key":"e_1_2_5_87_2","first-page":"863","article-title":"Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen","volume":"8","author":"Atkinson C.","year":"1999","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"e_1_2_5_88_2","doi-asserted-by":"crossref","unstructured":"Pollak M. J. Costantino C. Polychronakos et al.1990. Effect of tamoxifen on serum insulin\u2010like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer Inst.82:1693\u20101697.","DOI":"10.1093\/jnci\/82.21.1693"},{"key":"e_1_2_5_89_2","doi-asserted-by":"crossref","unstructured":"Hankinson S.E. W. C. Willett G.A. Colditz et al.1998. Circulating concentrations of insulin\u2010like growth factor\u2010I and risk of breast cancer. Lancet351:1393\u20101396.","DOI":"10.1016\/S0140-6736(97)10384-1"},{"key":"e_1_2_5_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70038-1"},{"key":"e_1_2_5_91_2","unstructured":"Dowsett M. Y. Lu M. Hills et al.1999. Effect of raloxifene on Ki67 and apoptosis. Breast Cancer Res.57:26 (abstract)."},{"key":"e_1_2_5_92_2","first-page":"2260","article-title":"Antiproliferative effects of Idoxifene in a placebo\u2010controlled trial in primary human breast cancer","volume":"6","author":"Dowsett M.","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_5_93_2","unstructured":"Robertson J.F.R. M. Dixon N. Bundred et al.1999. A partially\u2010blind randomised multicentre study comparing the anti\u2010tumor effects of single doses (50 125 and 250 mg) of long\u2010acting (LA) \u2018faslodex\u2019 (ICI 182 780) with tamoxifen in postmenopausal women with primary breast cancer prior to surgery. Breast Cancer Res. Treat.57:31 (abstract)."},{"key":"e_1_2_5_94_2","unstructured":"Fabian C.J. B.F. Kimler J. Anderson et al.2000. Phase I biomarker and toxicity evaluation of LY353381 (a 3rdgeneration selective estrogen receptor modulator SERM) in breast cancer. Proc. Am. Soc. Clin. Oncol.19:75a (abstract)."},{"key":"e_1_2_5_95_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4741.2000.99043.x"},{"key":"e_1_2_5_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116744"},{"key":"e_1_2_5_97_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.415"},{"key":"e_1_2_5_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.21.1624"},{"key":"e_1_2_5_99_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1217"},{"key":"e_1_2_5_100_2","unstructured":"Kimler B.F. C.M. Zalles S. Masood et al.2001. Phase II chemoprevention trial of \u03b1\u2010Difluoromethylornithine (DFMO) in women at high risk for breast cancer: surrogate endpoint biomarkers. Proc. Am. Assoc. Cancer Res.42:826 (Abst.)."},{"key":"e_1_2_5_101_2","unstructured":"Fabian C.J. B.F. Kimler D.A. Brady et al.2001. No detectable improvement in clinical parameters or increased side effects in a placebo\u2010controlled phase II breast chemoprevention trial of \u03b1\u2010difluromethylornithine (DFMO). Proc. Am. Assoc. Cancer Res.42:308 (Abst.)."},{"key":"e_1_2_5_102_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901001)66:7<1480::AID-CNCR2820660708>3.0.CO;2-O"},{"key":"e_1_2_5_103_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(1997)28\/29 <21::AID-JCB4>3.0.CO;2-Y"},{"key":"e_1_2_5_104_2","unstructured":"Andrews V. 2000. Breast cytology results from serial fine needle aspiration (FNA) in a high risk population. Proc. Am Soc. Clin. Oncol. 19:150a (abstract)."},{"key":"e_1_2_5_105_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)37755-9","article-title":"LY33381\u00b7HCl: a novel raloxifene analogue with improved SERM potency and efficacy in vivo","volume":"287","author":"Sato M.","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_5_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3808"},{"key":"e_1_2_5_107_2","unstructured":"Buzdar A. J.M. Nabholtz J.F. Robertson et al.2000. Anastrozole (arimidex) versus tamoxifen as first\u2010line therapy for advanced breast cancer (Abc) in postmenopausal (Pm) women\u2014combined analysis from two identically designed multicenter trials. Proc. Am. Soc. Clin. Oncol.19:154a (abstract)."},{"key":"e_1_2_5_108_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006293422603"},{"key":"e_1_2_5_109_2","unstructured":"Chan K.C. W.F. Knox J.R. Woodburn et al.1999. ZD1839 (Iressa\u2122) an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor inhibits proliferation in normal and preinvasive breast epithelia. Proceedings of the AACR\u2010NCI\u2010EORTC International Conference; Clinical Cancer Res.5(Suppl.): (abstract 27)."},{"key":"e_1_2_5_110_2","first-page":"1876","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case\u2010control study","volume":"356","author":"Narod S.A.","year":"2000","journal-title":"Hereditary Breast Cancer Clinical Study Group. Lancet"},{"key":"e_1_2_5_111_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.18.2251"},{"key":"e_1_2_5_112_2","first-page":"3867","article-title":"A potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling A.E.","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_5_113_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.9.4037"},{"key":"e_1_2_5_114_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo-129-4-2000"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb02727.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2001.tb02727.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2001.tb02727.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T04:57:37Z","timestamp":1740286657000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2001.tb02727.x"}},"subtitle":["New Endpoints for Breast Cancer Chemoprevention, New Drugs for Breast Cancer Prevention"],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1111\/j.1749-6632.2001.tb02727.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb02727.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"type":"print","value":"0077-8923"},{"type":"electronic","value":"1749-6632"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}